Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (G0F8516N, G065721N)
Alzheimer's Association (22-AAIIA-963171)
SAO/FRA Stichting Alzheimer Onderzoek (2023/0009)
Onderzoeksraad, KU Leuven (C14-17-107, C14/22/132, DB/20/007/BM)
Article History
Received: 19 January 2024
Revised: 13 March 2024
Accepted: 19 March 2024
First Online: 7 April 2024
Declarations
:
: DRT received consultant speaker honorary from Biogen (USA), travel reimbursement from GE-Healthcare (UK) and UCB (Belgium), and collaborated with Novartis Pharma AG (Switzerland), Probiodrug (Germany), GE-Healthcare (UK), and Janssen Pharmaceutical Companies (Belgium). DRT is a member of Acta Neuropathologica editorial board. He was not involved in the assessment or decision-making process for this manuscript.